Icatolimab (TAB004/JS004) is a humanized recombinant IgG4 monoclonal antibody against B- and T-lymphocyte attenuation factor (BTLA). In vitro and in vivo studies have shown TAB004 or JS004 can promote antigen specific T
cell proliferation and effector function, reduce tumor burden and improve survival in human BTLA knock-in tumor models.
Specifications
Catalog Number:
KB-1080
Antibodies Name:
Icatolimab
Host Cell Line:
EXPI-CHO
Target:
BTLA
Species Reactivity:
Human
Application:
ELISA | FACS | FACS Blocking
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
1.Bosch F, Dalla-Favera R (2019) Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol 16:684ÿ701.
2.Burger JA, O£ªBrien S (2018) Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol 15:510ÿ527.
